JP2012520084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520084A5 JP2012520084A5 JP2011554266A JP2011554266A JP2012520084A5 JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5 JP 2011554266 A JP2011554266 A JP 2011554266A JP 2011554266 A JP2011554266 A JP 2011554266A JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- virus
- protein
- present
- heterologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 claims description 188
- 210000004027 cell Anatomy 0.000 claims description 60
- 241000124008 Mammalia Species 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 53
- 241000700605 Viruses Species 0.000 claims description 33
- 230000028993 immune response Effects 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 32
- 239000002157 polynucleotide Substances 0.000 claims description 32
- 102000040430 polynucleotide Human genes 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 238000004806 packaging method and process Methods 0.000 claims description 24
- 210000004962 mammalian cell Anatomy 0.000 claims description 23
- 108700004025 env Genes Proteins 0.000 claims description 19
- 101150030339 env gene Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 18
- 230000002519 immonomodulatory effect Effects 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 101710172711 Structural protein Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 241000725619 Dengue virus Species 0.000 claims description 10
- 230000003362 replicative effect Effects 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 241001115402 Ebolavirus Species 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 5
- 241000713196 Influenza B virus Species 0.000 claims description 5
- 241001115401 Marburgvirus Species 0.000 claims description 5
- 241000711950 Filoviridae Species 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000004779 membrane envelope Anatomy 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 101710177291 Gag polyprotein Proteins 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims description 2
- 101710125418 Major capsid protein Proteins 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 61
- 102100034349 Integrase Human genes 0.000 description 57
- 101710091045 Envelope protein Proteins 0.000 description 31
- 101710188315 Protein X Proteins 0.000 description 31
- 108010061833 Integrases Proteins 0.000 description 30
- 230000001177 retroviral effect Effects 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 230000030833 cell death Effects 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 102100037357 Thymidylate kinase Human genes 0.000 description 8
- 101710102179 Thymidylate kinase Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 108090000565 Capsid Proteins Proteins 0.000 description 7
- 102100023321 Ceruloplasmin Human genes 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 108700004029 pol Genes Proteins 0.000 description 4
- 101150088264 pol gene Proteins 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 101150098622 gag gene Proteins 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16028509P | 2009-03-13 | 2009-03-13 | |
| US61/160,285 | 2009-03-13 | ||
| US16676909P | 2009-04-05 | 2009-04-05 | |
| US61/166,769 | 2009-04-05 | ||
| US16708809P | 2009-04-06 | 2009-04-06 | |
| US61/167,088 | 2009-04-06 | ||
| PCT/US2010/027262 WO2010105251A2 (en) | 2009-03-13 | 2010-03-13 | Non-integrating retroviral vector vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520084A JP2012520084A (ja) | 2012-09-06 |
| JP2012520084A5 true JP2012520084A5 (enExample) | 2013-04-25 |
Family
ID=42729161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554266A Withdrawn JP2012520084A (ja) | 2009-03-13 | 2010-03-13 | 非組み込み型レトロウイルスベクターワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120135034A1 (enExample) |
| EP (1) | EP2405945A4 (enExample) |
| JP (1) | JP2012520084A (enExample) |
| CN (1) | CN102438658A (enExample) |
| CA (1) | CA2754603A1 (enExample) |
| RU (1) | RU2012140691A (enExample) |
| WO (1) | WO2010105251A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013139565A (ru) * | 2011-01-27 | 2015-03-10 | Лентиджен Корпорейшн | Усовершенствованная праймерная и бустерная вакцина |
| AU2012267512B2 (en) * | 2011-06-10 | 2014-11-20 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
| US9713635B2 (en) * | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| EP2831095B1 (en) | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| ES2745103T3 (es) * | 2013-06-15 | 2020-02-27 | Tocagen Inc | Partículas inmunosupresivas similares a virus basadas en gammaretrovirus |
| EP2878674A1 (en) * | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| AU2015247727A1 (en) | 2014-04-15 | 2016-11-03 | University Of Virginia Patent Foundation | Isolated T cell receptors and methods of use therefor |
| MA41382A (fr) * | 2015-03-20 | 2017-11-28 | Univ Temple | Édition génique basée sur le système crispr/endonucléase à induction par tat |
| US20180094280A1 (en) * | 2015-03-20 | 2018-04-05 | Bluebird Bio, Inc. | Vector formulations |
| US11078495B2 (en) | 2015-10-15 | 2021-08-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration defective lentiviral vectors |
| GB201715052D0 (en) * | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| CA3083772A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| RU2680703C1 (ru) * | 2018-02-13 | 2019-02-25 | Общество с ограниченной ответственностью "Нанолек" | Кассета, предназначенная для получения плазмидных векторов, используемых для создания клеток-продуцентов вирусоподобных частиц (ВПЧ) вируса гриппа |
| RU2681439C1 (ru) * | 2018-02-13 | 2019-03-06 | Общество с ограниченной ответственностью "Нанолек" | Вирусоподобная частица вируса гриппа и способ ее получения |
| RU2681482C1 (ru) * | 2018-02-13 | 2019-03-06 | Общество с ограниченной ответственностью "Нанолек" | MDCK клетка-продуцент белков вируса гриппа (варианты) |
| RU2680537C1 (ru) * | 2018-02-13 | 2019-02-22 | Общество с ограниченной ответственностью "Нанолек" | Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты) |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020112904A1 (en) | 2018-11-26 | 2020-06-04 | Massachusetts Institute Of Technology | Compositions and methods for immune tolerance |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| MX2023001028A (es) | 2020-07-24 | 2023-04-24 | Massachusetts Gen Hospital | Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas. |
| EP4423288A4 (en) * | 2021-10-25 | 2025-09-10 | Genvivo Inc | COMPOSITIONS AND METHODS OF THERAPEUTIC OR VACCINAL ADMINISTRATION |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046083A1 (en) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO2004029246A2 (en) * | 2002-09-26 | 2004-04-08 | K.U.Leuven Research And Development | Integrase cofactor |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| EP1677832A1 (en) * | 2003-09-09 | 2006-07-12 | VIRxSYS Corporation | Lentivirus vector-based approaches for generating an immune response to hiv humans |
| WO2005034992A2 (en) * | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hif |
| FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| JP2008521405A (ja) * | 2004-11-24 | 2008-06-26 | ナノヴェクター・リミテッド | ウイルスベクター |
| WO2006089001A2 (en) * | 2005-02-16 | 2006-08-24 | Lentigen Corporation | Lentiviral vectors and their use |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| DK2020444T3 (en) * | 2007-08-03 | 2017-09-11 | Pasteur Institut | DEFECTIVE NON-INTEGRATIVE LENTIVIRAL TRANSMISSION VECTORS FOR VACCINES |
-
2010
- 2010-03-13 CN CN2010800204988A patent/CN102438658A/zh active Pending
- 2010-03-13 RU RU2012140691/10A patent/RU2012140691A/ru not_active Application Discontinuation
- 2010-03-13 EP EP10751533A patent/EP2405945A4/en not_active Withdrawn
- 2010-03-13 WO PCT/US2010/027262 patent/WO2010105251A2/en not_active Ceased
- 2010-03-13 US US13/256,216 patent/US20120135034A1/en not_active Abandoned
- 2010-03-13 CA CA2754603A patent/CA2754603A1/en not_active Abandoned
- 2010-03-13 JP JP2011554266A patent/JP2012520084A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520084A5 (enExample) | ||
| US20120135034A1 (en) | Non-Integrating Retroviral Vector Vaccines | |
| CN110958887B (zh) | 编码hiv抗原的痘病毒载体及其使用方法 | |
| JP2018076363A (ja) | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 | |
| JP2013027396A (ja) | クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス | |
| Di Nunzio et al. | HIV-derived vectors for therapy and vaccination against HIV | |
| US20110142880A1 (en) | Lentivirus-based immunogenic vectors | |
| CN104039968B (zh) | 非b亚型gag蛋白在慢病毒包装中的应用 | |
| JP2024502658A (ja) | 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン | |
| CA2825032A1 (en) | Advanced prime and boost vaccine | |
| EP1543837A1 (en) | Virus-like particle (VLP) as vaccine | |
| RU2697781C2 (ru) | Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека | |
| Wang et al. | Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls... | |
| McKenna | Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins | |
| HK1200870B (en) | Use of non-subtype b gag proteins for lentiviral packaging |